Should Airway Hyper-Responsiveness Be Included in the Definition of Clinical Remission With Biologic Therapy in Severe Asthma

Brian Lipworth; Chris RuiWen Kuo; Kirsten Stewart; Rory Chan

doi:10.1016/j.jaip.2023.12.013

Should Airway Hyper-Responsiveness Be Included in the Definition of Clinical Remission With Biologic Therapy in Severe Asthma

J Allergy Clin Immunol Pract. 2024 Apr;12(4):904-907. doi: 10.1016/j.jaip.2023.12.013. Epub 2023 Dec 12.

Authors

Brian Lipworth¹, Chris RuiWen Kuo², Kirsten Stewart², Rory Chan²

Affiliations

¹ Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Dundee, United Kingdom. Electronic address: b.j.lipworth@dundee.ac.uk.
² Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Dundee, United Kingdom.

PMID: 38097177
DOI: 10.1016/j.jaip.2023.12.013

Abstract

Airway hyper-responsiveness (AHR) is a tenet of the persistent asthma phenotype along with reversible airway obstruction and type 2 (T2) inflammation. Indirect acting challenges such as mannitol are more closely related to the underlying T2 inflammatory process as compared with direct challenges. In this review article, we summarise the current literature and explore the future role of mannitol AHR in clinical remission with biologics.

Keywords: Airway hyper-responsiveness; Asthma; Biologic; Remission.

Publication types

Review

MeSH terms

Asthma* / drug therapy
Biological Therapy
Humans
Inflammation
Mannitol / therapeutic use
Respiratory Hypersensitivity*

Substances

Mannitol